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Dengue is the most prevalent mosquito-borne viral
disease in humans, and the lack of early prognostics,
vaccines, and therapeutics contributes to immense
disease burden. To identify patterns that could be
used for sequence-based monitoring of the antibody
response to dengue, we examined antibody heavy-
chain gene rearrangements in longitudinal peripheral
blood samples from 60 dengue patients. Comparing
signatures between acute dengue, postrecovery,
and healthy samples, we found increased expansion
of B cell clones in acute dengue patients, with higher
overall clonality in secondary infection. Additionally,
we observed consistent antibody sequence features
in acute dengue in the highly variable major antigen-
binding determinant, complementarity-determining
region 3 (CDR3), with specific CDR3 sequences high-
ly enriched in acute samples compared to postrecov-
ery, healthy, or non-dengue samples. Dengue thus
provides a striking example of a human viral infection
where convergent immune signatures can be identi-
fied in multiple individuals. Such signatures could
facilitate surveillance of immunological memory in
communities.
INTRODUCTION
Nearly three billion people worldwide are at risk for infection with
dengue virus (DENV) (WHO, 2012), a mosquito-borne Flavivirus.
There are four phylogenetically distinct serotypes of DENV
(DENV-1 to DENV-4), all of which cause a spectrum of clinical
manifestations ranging from asymptomatic infection to the
debilitating acute febrile illness, dengue fever (DF), to the life-
threatening dengue hemorrhagic fever (DHF) and dengue shock
syndrome (DSS) (WHO, 1997). Key determinants of dengueCell Hpathogenesis include pre-existing host immunity from prior
infection(s) with a distinct DENV serotype and differential viru-
lence of the infecting DENV strain (Halstead and Yamarat,
1965; Messer et al., 2003; Rico-Hesse et al., 1997). Enhanced
pathogenicity in sequential DENV infections may be due to sub-
optimal immune responses contributed by pre-existing memory
B and T cells that were primed by viral antigens from the first
infection rather than the naive B and T cells primed during the
current infection (Halstead, 1988, 2009; Peiris and Porterfield,
1979; Rothman and Ennis, 1999). In addition, cytokines released
by immune effector cells can play dual roles in attenuating and/or
exacerbating disease pathogenesis in dengue (Avirutnan et al.,
2007; Rothman and Ennis, 1999). Such complex interactions
between protective and enhancing components of the immune
response in dengue have made it difficult to identify the precise
mechanisms that trigger progression to severe disease.
Severe disease only occurs in a few percent of symptomatic
DENV infections. Yet, dengue imposes a major burden on health
care systems. This is due to the absence of prognostic bio-
markers for severe disease, resulting in a situation where many
patients presenting with uncomplicated DENV infections are
hospitalized due to difficulties in early identification of high-risk
infections. This, together with geographic expansion in dengue
transmission and a lack of licensed vaccines and therapeutics,
has made dengue a major global health problem.
In this study, we employ high-throughput sequencing meth-
odologies to investigate immunoglobulin heavy-chain gene
rearrangement signatures from 60 individuals enrolled in pro-
spective dengue studies in Nicaragua. Recent advances in
high-throughput sequencing of antibody repertoires have facili-
tated the exploration of heavy-chain signatures in zebrafish
(Weinstein et al., 2009), mice (Reddy et al., 2010), and humans
(Arnaout et al., 2011; Boyd et al., 2009; Liao et al., 2011; Praba-
karan et al., 2012; Wu et al., 2011). In particular, investigations
of antibody signatures in healthy individuals and individuals
with hematological pathologies have emphasized the utility of
heavy-chain sequencing in tracking disease in humans (Boyd
et al., 2009; Logan et al., 2011). Here, we use sequence-based
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Table 1. Samples Used in This Study
Disease Severity
Individuals with
Primary Infection
Individuals with
Secondary Infection Cases with Three
Available Time Pointsa
Total Samples
(All Time Points)DENV-2 DENV-3 DENV-2 DENV-3
Dengue fever 4 7 6 6 20 55
Dengue hemorrhagic fever 1 4 0 5 9 24
Dengue shock syndrome 1 0 10 0 9 21
Non-dengue febrile illness NA NA NA NA NA 8
Healthy NA NA NA NA NA 8
NA, not available. See also Table S1.
aCases with all three time points available: 2–4 days, 14 days, and 6 months postsymptom onset.
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B cells or antigen specificity in order to identify convergent immu-
noglobulin sequence correlates that are specific to acute
dengue, diminished after resolution of infection, and absent in
non-dengue samples.
RESULTS AND DISCUSSION
Description of Samples and Methods
PBMCswere sampled from 44 individuals exposed toDENVdur-
ing acute symptomatic dengue at 2–5 days postsymptom onset
(dpo), convalescence (7–47 dpo), and after convalescence
(180 dpo) (Table 1 and Table S1 available online). The availabil-
ity of longitudinal samples facilitated assessment of infection-
associated signatures (acute phase), persistence of signatures
after clearance of infection (convalescent phase), and baseline
profiles (postconvalescent phase) within the same individual.
We also evaluated PBMCs sampled from eight individuals with
non-dengue febrile illness and eight healthy individuals with no
prior history of dengue (Tables 1 and S1). All individuals were
enrolled in one of two Nicaraguan studies (see Experimental Pro-
cedures) (Hammond et al., 2005; Kuan et al., 2009) and were
chosen to ensure an adequate, unbiased representation of
primary and secondary apparent infections with DENV-2 or
DENV-3. Supporting clinical information, such as dengue
immune status, disease severity, and infecting DENV serotype,
is available for all samples (Tables 1 and S1).
Rearranged antibody heavy-chain variable region (VH) seg-
ments were amplified from100 ng of PBMCDNAusing barcoded
primers in six independent PCR reactions (as previously
described by Boyd et al., 2009). The use of genomic DNA as
the template for PCR ensures that each B cell contributes a sin-
gle copy of its rearranged immunoglobulin locus to the template
pool. Multiple PCR libraries therefore provide sampling of inde-
pendent B cell populations. Sequences observed in more than
one PCR library are derived from sufficiently large B cell clones
such that members of these clones populate templates used
to generate multiple PCR libraries (Boyd et al., 2009). Thus, repli-
cate sequencing allows us to estimate the size of B cell clones,
with relative abundance proportional to the number of replicates
in which the clone is detected (Boyd et al., 2009).
All VH libraries were sequenced twice by independent runs on
a GS FLX System (454 Life Sciences, Roche) (Margulies et al.,
2005). Sequences were segregated based on DNA barcodes,
and VH rearrangements were aligned to germline gene reper-692 Cell Host & Microbe 13, 691–700, June 12, 2013 ª2013 Elseviertoires using the iHMMune-align algorithm (Gae¨ta et al., 2007;
Jackson et al., 2010). Resulting alignments were parsed to
obtain V, D, and J matches. Only alignments that were in-frame
and could produce functional protein were further considered.
Additionally, data filtering steps were implemented to remove
potential PCR contaminants and improperly amplified PCR
products that were inappropriately found in multiple samples
(see Experimental Procedures). We also chose to exclude
sequences lacking both VD andDJ junctional bases, since these
are more likely to occur independently in different individuals.
Sequences with unassigned D regions were retained in our anal-
ysis. After filtering, the read count per sample varied between
450 and 9,000, with a median count of 2,000 (Table S1).
VH Signatures in Acute Dengue
Clonal expansions of immune cells have been observed in many
pathological states such as viral and bacterial infections and
hematological malignancies (Thorse´lius et al., 2006; Wang and
Palese, 2009; Zhou et al., 2002). VH sequencing has facilitated
the identification of prominent clonal B cell populations in
lymphocytic malignancies, without prior selection for specific
classes of B cells (Cleary et al., 1984; Warnke and Levy, 1978).
Less-prominent B cell clones are also evident in sequence
data sets from healthy individuals and can be detected by
identification of identically rearranged sequences in PCR
pools generated from independent cellular DNA aliquots from
the same sample (Boyd et al., 2009). Such VH ‘‘coincident
sequences’’ were found to be extremely rare between samples
from different individuals, due to the substantial combinatorial
and junctional diversity of immunoglobulin gene rearrangements
(Boyd et al., 2009; Glanville et al., 2011).
The presence of clonal populations in a sample may be esti-
mated using various diversity indices (for example, Hill, 1973;
Jost, 2006) to calculate clonality scores from a single DNA
pool per sample. In our study, we apply a replicate library
sequencing approach to robustly test for the presence of clonal
B cell populations in an individual by sequencing from multiple
distinct DNA aliquots isolated from the same lymphocyte sample
(Boyd et al., 2009). We use the probability of identifying clonally
related sequences in arbitrary sequence pairs from different
aliquots of a single sample (P[collision]) (Schnabel, 1938) as a
metric to track clonality. P(collision) captures the probability
that any two randomly chosen B cells in an individual share a
clonal origin, with mean values of P(collision) independent of
sequencing depth (Figures S1A and S1B).Inc.
Figure 1. Antibody VH Clonality in Peripheral Blood as a Surrogate for B Cell Expansion in Human Dengue
(A) Probability of observing identical VH sequences in two or more independent PCR replicates (P[collision]) in acute- and convalescent (Conv)-phase samples
(left panel, *p = 0.0004, Wilcoxon signed-rank test) or in acute- and postconvalescent (P-Conv)-phase samples (right panel, *p < 0.0001, Wilcoxon signed-rank
test) from the same patients. Only convalescent samples that were taken 7–21 dpo were considered for this analysis.
(B) P(collision) measures for samples from healthy individuals and individuals with acute, non-dengue febrile illness (febrile). *p = 0.0486, Wilcoxon-Mann-
Whitney test.
(C) P(collision) in acute (left panel)-, convalescent (middle panel)-, or postconvalescent (right panel)-phase samples from individuals presenting with primary or
secondary DENV infections. *p = 0.0409, Wilcoxon-Mann-Whitney test. In (B) and (C), annotations to each plot show the 25th–75th percentiles (box), the 10th–90th
percentiles (whiskers), and the median (horizontal line). See also Figure S1 and Table S2.
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higher in acute-phase samples compared to convalescent or
postconvalescent samples from the same individual (p =
0.0004 and p < 0.0001, respectively) (Figure 1A, left and right
panels, and Table S2). We also detected higher P(collision)
scores in samples from individuals with non-dengue febrile
illnesses in contrast to samples from healthy individuals (p =
0.0486) (Figure 1B and Table S2). These results illustrate that
quantifiable measurements of VH clonality in peripheral blood
samples are able to capture global (if not pathogen-specific) dif-
ferences in B cell populations associated with diverse illnesses.
We next compared P(collision) scores between primary and
secondary acute DENV infections and observed a significant
increase in secondary acute cases (p = 0.0409) (Figure 1C, left
panel). No such difference was detected for convalescent or
postconvalescent samples (Figure 1C, middle and right panels).
P(collision) was also significantly higher in acute samples
compared to convalescent or postconvalescent samples for
secondary dengue (p = 0.0046 for acute and convalescent and
p < 0.0001 for acute and postconvalescent comparisons) but
not for primary dengue (Figures S1C and S1D, left and middle
panels). Taken together, our observations suggest that the clon-
ality of the B cell response in peripheral blood is significantly
higher in secondary dengue compared to primary dengue.
Convergent CDR3s in Acute Dengue
The VH protein tertiary structure includes three exposed loop
regions that are involved in antigen recognition (complemen-Cell Htarity-determining regions CDR1, CDR2, and CDR3) and four
framework regions (FR1, FR2, FR3, and FR4) that form the scaf-
folds for the CDR loops. All FRs and CDRs are encoded entirely
by germline V or J genes, except for CDR3, which is encoded by
recombined sequences from V, D, and J genes (Jung et al.,
2006). Due to the junctional diversity created by V-D-J recombi-
nation processes, the CDR3 is the most diverse region in the VH
peptide sequence (Tonegawa, 1983). CDR3s are suggested to
be the major determinant of antibody specificity (Xu and Davis,
2000), with some contributions from residues in CDR1 or
CDR2 (Ekiert et al., 2009; Padlan et al., 1989). The probability
of finding identical antibody sequences in different individuals
is reported to be extremely low, even in monozygotic twins
(Glanville et al., 2011), and it is often assumed that individuals
use distinct antibody sequences, in particular, distinct CDR3s,
in response to the same antigen. Several studies have investi-
gated CDR3 usage in antigen-specific antibody populations by
leveraging sequence information from monoclonal antibodies
that bind an antigen of interest in order to subsequently identify
similar sequences using deep sequencing of whole-blood PBMC
populations (Chen et al., 2012; Prabakaran et al., 2012; Wu et al.,
2011). Less than 50% sequence similarity was observed in anti-
gen-specific CDR3s from different individuals (Prabakaran et al.,
2012; Wu et al., 2011).
We sought to ascertain CDR3 signatures that were specific to
the human immune response to dengue without preselecting for
antigen-specific B cells. Cross-validation was used for the selec-
tion of predictive CDR3s that were highly prevalent in acuteost & Microbe 13, 691–700, June 12, 2013 ª2013 Elsevier Inc. 693
Figure 2. CDR3 Prevalence in Dengue and
Non-Dengue Samples
(A and B) Prevalence of selected CDR3s,
measured as proportion of samples containing
these CDR3s in various subsets of samples. (A)
CDR3 prevalence in acute-phase samples parti-
tioned for cross-validation or by DENV serotype.
(B) CDR3 prevalence in samples from 47 healthy
individuals and 8 individuals with non-dengue
febrile (non-dengue) and in postconvalescent-
phase samples partitioned either for cross-vali-
dation or by DENV serotype. See also Figure S2
and Table S3.
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samples from the same individual or in samples from healthy
individuals. Prevalence (or incidence) of a CDR3 is defined as
the proportion of samples containing the CDR3 of interest. The
data set was first partitioned by randomly assigning the 44 indi-
viduals into 2 nonoverlapping groups of 22 individuals (Fig-
ure S2A). We then assessed the prevalence of all CDR3s and
their one-mismatch derivatives (i.e., CDR3s that differ by one
amino acid) for one of the two groups (the training set). Ten
CDR3s were highly prevalent in acute dengue cases in the
training set (Figure S2B), of which six CDR3s were found to be
absent or of low prevalence in postconvalescent samples from
the same set of individuals (Figures 2A and 2B). The incidence
of these six CDR3s was then evaluated in the second group of
individuals (first test set). Notably, five of the six CDR3s were
highly prevalent in acute dengue cases in the first test set
(Figure 2A) and nearly absent in postconvalescent samples
(Figure 2B). This bias in prevalence is not due to differences in
sequencing depth, as samples having or lacking convergent
CDR3s had comparable sequencing coverage (Figure S2C).
We next examined whether these CDR3s could be detected in
an independent set of samples from 16 individuals with acute
dengue (second test set; Table S1) that were processed using
an amplification strategy similar to the original data set. All six
CDR3s were found in a substantial proportion of dengue sam-
ples in the second test set (Figure 2A). Swapping the training
and test sets (i.e., identifying CDR3s using the first test set and694 Cell Host & Microbe 13, 691–700, June 12, 2013 ª2013 Elsevier Inc.validating on the training set and the sec-
ond test set) also yielded similar 10-mer
and 13-mer CDR3 candidates (Fig-
ure S2D). Alternative partitioning of the
data set by DENV serotype illustrated
that these CDR3 signatures were associ-
ated with both DENV-2 and DENV-3 in-
fections but were barely discernible after
resolution of infection (Figures 2A and
2B). Furthermore, these CDR3 se-
quences and their one-mismatch deriva-
tives were absent or extremely rare in
non-dengue samples from 47 healthy in-
dividuals enrolled in Nicaraguan- (Ham-
mond et al., 2005; Kuan et al., 2009)
and US-based (Boyd et al., 2010; Boyd
et al., 2009; Kidd et al., 2012) studiesand from 8 individuals who presented with non-dengue febrile
illness (Figure 2B). We also examined over 1,000 immunoglob-
ulin sequence data sets derived from 640 individuals enrolled
in a number of distinct studies from the authors and collabo-
rating groups where identical primer design was used; none of
these samples showed precise matches to the identified
CDR3s (data not shown).
In addition to mismatch-based cross-validation, we evaluated
four independent approaches for identifying CDR3s that were
prevalent in acute dengue cases (see Experimental Procedures).
Substantial similarities were observed in the 10-mer and 13-mer
CDR3 subsets that were predicted to be dengue specific using
these various approaches (Figure S2F and Table S3). We have
thus identified several 10-mer and 13-mer VH CDR3s in B cell
repertoires from unsorted PBMCs that appear to be unique
signatures of the human immune response to DENV infection.
Notably, the dengue-specific CDR3s appear to be relatively
short, with minor contributions from D gene sequences. It is
conceivable that convergent sequences with longer CDR3s
may be less common, simply due to the greater diversity inherent
in long CDR3 sequences. Short CDR3 signatures are typically
seen in fetal and neonatal B cell repertoires (Souto-Carneiro
et al., 2005; Zemlin et al., 2001). Yet, we found no association
between the presence of these short CDR3s in the sampled pop-
ulation and underlying age structures (Figure S2G), suggesting
that the identification of short convergent CDR3 species is not
due to skewed sampling from neonates or very young infants.
Figure 3. Diversity in Sequences Encoding
for the ARLD(Y)5GMDL CDR3
Nucleotide sequences encoding for the
ARLD(Y)5GMDL CDR3, segregated by patient
identity and sample type (A, acute; C, convales-
cent; PC, postconvalescent). #, count per sample;
CON, consensus; V, variable region; D, diversity
region; N, nontemplated additions; J, joining
region; *^identical sequences in multiple samples.
See also Figure S3.
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dances ranging from a relatively low 0.01% up to 1% of all
sequenced VH for each sample (Figure S3A), suggesting that
the convergent signatures contributed by these CDR3s are typi-
cally rare, but can represent a significant fraction of all B cells in
the blood.
Diversity in CDR3 Nucleotide Sequences
We explored the diversity in nucleotide sequences underlying
all CDR3 candidates identified by mismatch-based cross-
validation (Figures 3, 4, and S3B–S3F) but particularly focused
on ARLD(Y)5GMDL, which has the highest incidence among
all identified convergent CDR3 sequences, when not consid-
ering contributions from one-mismatch derivatives (data not
shown). Sequences encoding for all convergent CDR3s were
different across most individuals (Figures 3 and S3B–S3E),
with identical sequences found only in a handful of samples
(Figures 3 and S3C, identical sequences indicated by symbols).
Such sequence variation may be attributed to (i) independent
clonal lineages with equivalent rearrangements, (ii) sequence
variation due to somatic mutation in cells belonging to a single
clonal lineage derived from a single initial rearrangement, or
(iii) postextraction amplification or sequencing errors from uni-
form underlying sequences. Although (ii) and (iii) likely contribute
to observed sequence variation, the data strongly support a set
of independently derived rearrangements for these convergent
CDR3s due to several sequence-based observations. First, in
multiple individuals, sequences underlying the convergent
CDR3s exhibited numerous deviations from inferred germlineCell Host & Microbe 13, 691–7sequence (Figures 3 and S3C–S3E, high-
lighted nucleotides). Second, some of
these CDR3s and their derivatives
appear to be represented in several
distinct subclonal lineages within individ-
uals (Figure S4). Third, in all individuals
we found examples wherein the same
amino acid in the CDR3 was encoded
by divergent synonymous codons with
one or two base differences (Figures 3
and S3B–S3E). Fourth, we observed
substantial diversity in nucleotide se-
quences underlying FRs and CDRs both
upstream and downstream of the
CDR3, as illustrated for ARLD(Y)5GMDL
(Figure 4). Notably, much of this hetero-
geneity is explained by the usage of mul-
tiple V gene segments in encoding theCDR3 and its one-mismatch derivatives both within and across
individuals (Figure 4). Six distinct V genes from the V1, V3, or V5
gene families exhibited evidence for association with ARL-
D(Y)5GMDL and its one-mismatch derivatives in at least two
samples (Figure 4, ‘‘V gene usage’’). Likewise, multiple V genes
were used in encoding the other four CDR3s (Figure S3F). The
use of diverse V genes for encoding the prevalent CDR3s is un-
expected and provides strong support for the hypothesis that
the associated VH regions were generated by convergent evolu-
tion. Taken together, our observations suggest that these
CDR3s originated from distinct VH sequences in individuals
exposed to DENV and are not likely to represent PCR contam-
inants or artifacts.
Contributions from Affinity-Matured B Cells
B cells that have encountered antigens undergo successive
rounds of affinity maturation, during which B cells with optimal
antigenic affinity are selected as immune responders. B cells
undergoing affinity maturation accrue mutations in V, D, and
J germline sequences by a process known as somatic
hypermutation. The number of mutations observed in V gene
sequences has been commonly used for segregating sequence
features associated with naive and affinity-matured B cells
(Glanville et al., 2011; Wrammert et al., 2008).
We investigated whether the highly prevalent CDR3 signatures
were derived from affinity-matured B cells. For each primer-
trimmed V segment associated with these CDR3s, we calculated
the percent of nucleotides that were different from the closest
reference V gene germline sequence in the international00, June 12, 2013 ª2013 Elsevier Inc. 695
Figure 4. Sequence Diversity in Regions Flanking the ARLD(Y)5GMDL CDR3
Color-coded nucleotide diversity in FRs flanking the ARLD(Y)5GMDL CDR3 and its one-mismatch derivatives, with each row representing a unique sequence
read within an individual. %mut, percent mutation in the V gene (which has been truncated to include 160 nucleotides at the 30 terminus for direct comparison
between sequences); V gene usage, V genes with evidence for usage in at least two samples; sample, sample of sequence origin. See also Figure S4.
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V sequences had less than 1.9%mutation compared to germline
(three nucleotide changes) (Figures 4 and S3G), suggesting that
only a minor proportion of the convergent CDR3 signatures were
contributed by naive B cells. The median somatic mutation in
V gene segments associated with all convergent CDR3s varied
from 4.4% to 6.9% (7–11 mutations; Figures 4 and S3G), which
suggests that these CDR3s were likely derived from memory
B cell populations (Glanville et al., 2011). The highmutation score
was not attributable to differences in hypermutation frequencies
between VH rearrangements using different V segments, since
V sequences with less than 1.9% mutation (three nucleotide
changes) were significantly more abundant in other B cell popu-
lations that used the same subset of V genes for encoding other
CDR3s (p% 0.0001, Fisher’s test; Figure S3H). Antibodies with
these prevalent CDR3s thus appear to be derived from B cell
populations that have undergone affinity maturation and accu-
mulated somatic mutations in response to DENV infection.
Furthermore, the majority of convergent CDR3s were signifi-
cantly more prevalent in acute secondary dengue compared to
acute primary dengue (p% 0.05, Fisher’s test; Figure S3I). This
is consistent with a higher prevalence of infection-specific affin-
ity-matured B cell populations in secondary infections (Smith
et al., 1997).
Physicochemical Properties of Prevalent CDR3s
Affinity maturation selects CDRs with distinctive physicochem-
ical profiles that favor antigen recognition. The skewed represen-
tation of the convergent 10-mer and 13-mer CDR3s in affinity-
matured B cell populations suggests that the physicochemical
profiles of these CDR3s may define specific indicators of the
immune response in acute dengue. We hence probed for
coherent physicochemical properties associated with the
convergent 10-mer and 13-mer CDR3s.
We first identified other CDR3s that were similar to the con-
vergent CDR3s in amino acid physicochemical space, using
principal component analysis (PCA) and standard clustering
approaches to partition CDR3s based on molecular weight, iso-
electric pH, and hydrophilicity scores for each amino acid. We
note that, as predicted for a complex mixture, the use of a large
number of variables for PCA resulted in each principal compo-
nent accounting for only a modest proportion of total variation
between CDR3s. Nevertheless, we confirmed that clusters con-
taining the convergent 10-mer and 13-mer CDR3s exhibited
significantly higher prevalence in acute dengue subsets (Fig-
ure S5A and Table S4). Several other clusters that also appeared
to bemore prevalent in acute-phase samples (Table S4) were not
considered for further analysis because their members were not
identified as being convergent by statistically robust approaches
such as mismatch-based cross-validation and L1-regularized
logistic regression.
Interestingly, clusters containing the convergent CDR3s
appeared to occupy exclusive coordinate sets in CDR3 amino
acid physicochemical space bounded by the first three compo-
nents; these coordinates were sparsely populated by other
CDR3s from either dengue or non-dengue data sets (Figures
5A and 5B). Furthermore, several amino acids in CDR3s from
these clusters exhibited physicochemical scores that were
distinct from median scores for amino acids in other identical-Cell Hlength CDR3s (Figures 5C, S5B, and S5C). These CDR3 clusters
principally associated with convergent CDR1 and CDR2 clusters
that also exhibited several mutations relative to germline encod-
ing. Taken together, our observations suggest that the identi-
fied CDR3 sequences and their associated CDR2 and CDR1
sequences have coherent amino acid physicochemical profiles
that uniquely position them as immune repertoire indicators in
human dengue.
Conclusions
We have identified convergent dengue-specific immune reper-
toire signatures that define prevalent and specific indicators of
DENV infection. Such immune signatures may be amenable for
engineering protein- or nucleic acid-based diagnostic tools for
acute dengue or for surveying and tracking exposure to DENV
in endemic communities. This list of predictors is by no
means exhaustive, as it is conceivable that our algorithms for
mismatch-based and similarity-based querying overlooked
complex motifs encased in other convergent signatures. Similar
efforts to identify coherent antibody signatures in infections with
other microbial pathogens could reveal indicators for tracking
infections (particularly when other diagnostics are unavailable)
and immunological histories in individuals.
EXPERIMENTAL PROCEDURES
Ethics Statement
All studies were approved by the Institutional ReviewBoards of theNicaraguan
Ministry of Health and the University of California, Berkeley. Parents or legal
guardians of all pediatric subjects provided written consent, and assent was
obtained from subjects six years of age and older.
Study Population
PBMCs from subjects enrolled in one of two ongoing prospective studies of
dengue in Nicaragua were used. (1) The hospital-based study, ongoing since
2005 (Hammond et al., 2005), enrolls pediatric patients who present with sus-
pected dengue to the National Pediatric Reference Hospital in Managua.
PBMCs and plasma are collected from patients during the acute phase of
illness (2–5 dpo), at convalescence (14 dpo), and longitudinally at 3, 6, 12,
and 18 months. (2) The Pediatric Dengue Cohort Study (2004–present; Kuan
et al., 2009) follows 3,800 children in District II of Managua. Each year, a
blood sample is drawn from all subjects during the dry season, which has a
low incidence of dengue, to assess prior exposures to DENV. Additionally,
acute- and convalescent-phase samples are collected year round from partic-
ipants who present with suspected dengue or undifferentiated febrile illness.
Extensive epidemiological and clinical data are available for all samples.
Criteria for identification of dengue-positive cases and for classification by
immune status are as described (Harris et al., 2000). Samples from symptom-
atic individuals that do not meet these criteria are classified as non-dengue
febrile. Samples from healthy individuals enrolled in the prospective cohort
study with no prior history of dengue or anti-DENV antibodies are classified
as healthy. Classification of dengue cases as DF, DHF, or DSS is according
to the World Health Organization’s guidelines (WHO, 1997).
Data Filtering
The BIOMED-2 multiplex primer combinations (Boyd et al., 2010) generate a
small proportion of artifactual sequences during PCR. These sequences can
be distinguished by their occurrence in amplified human DNA from nonlym-
phoid cell lines, by the general absence of strongly assignable D regions,
and by anomalous positioning of break points relative to expected V and J
recombination junctions. A naive Bayes classifier was trained to discriminate
such ‘‘spam’’ sequences from bona fide ‘‘non-spam’’ rearrangements as
follows: (1) sequences from previous analyses were aligned using iHMMune-
align, and potentially artifactual cross-specimen recurrences were labeledost & Microbe 13, 691–700, June 12, 2013 ª2013 Elsevier Inc. 697
Figure 5. Amino Acid Characteristics of Coherent CDR3s
(A and B) Separation of CDR3 clusters in the spaces bounded by principal
components (Prin) 1, 2, and 3, which represent residue-by-residue scores for
hydrophilicity, molecular weight, and isoelectric pH for all CDR3s with VH
usage and length identical to the convergent 13-mer (A) and 10-mer (B)
CDR3s. All CDR3s that cluster with the 13-mer and 10-mer CDR3s identified
by mismatch cross-validation are highlighted; members from all other clusters
are faded. The top right quadrants are magnified images of the boxed graph
areas.
(C) Sequences and residue-specific characteristics of VH CDR1s and CDR2s
associated with the highlighted 13-mer (top panel) and 10-mer (bottom panel)
convergent CDR3 clusters. Amino acids in black, consensus residues; amino
acids in red, germline-encoded residues different from consensus; *junctional
residues with indeterminable germline sequence. Colored circles indicate
deviations in molecular weight, isoelectric pH, or hydrophilicity scores from
germline encodings for CDR1 and CDR2 or from median scores computed
across all CDR3s with lengths identical to the corresponding CDR3s. See also
Figure S5 and Table S4.
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combined with specific sequences in the putative junctions that could be pre-
dicted strongly by assigning Bayesian probabilities to all k-mers (k = 1, 2, 3, 4,
5, or 6) in each junction, were used to generate a comprehensive model list of
spam sequences; (3) for any clone, the product of relative frequencies of each
assigned V-J segment and junction k-mer in spam versus non-spam provided
a likelihood estimate for assigning spam. We note that only a small number of
sequences scored as spam in these analyses (Table S1) and, upon inspection,
the vast majority of these clearly resemble recurrent nonlymphoid sequences
(Boyd et al., 2009).
In addition to the filtering of artifactual sequences, reads containing
common pyrosequencing errors, such as insertions and deletions (indels)
focused at homopolymer tracts, were also removed (Table S1). Indels in
the V and J regions were identified by extending iHMMune-align to include
a preliminary BLAST (Altschul et al., 1990) against the V and J germline
repertoires. If an alignment between a read and the germline V or J included
indels (gaps), then the germline repertoire used for iHMMune-align map-
ping was updated to include a version of the gene with indels for use in
model building. This allowed iHMMune-align to provide mappings for
sequences with V or J indels. Sequences that included indels within the
junction region (N1, D, N2) were largely excluded by only analyzing in-frame
rearrangements.
Alternative Approaches for Identifying Convergent CDR3s
(1) We implemented a simple scoring system using a modified BLOSUM62
similarity matrix (Figure S2E) to calculate an overall score for each CDR3.
Derivatives for each CDR3 were identified using a cutoff of R95% for score
similarity, and cross-validation was used to discern CDR3s with the highest
prevalence (Figure S2F). (2) We employed an association-based analysis
using Holm-Bonferroni adjusted p values and Benjamini-Hochberg false dis-
covery rate (FDR) estimates to identify CDR3s and their one-mismatch deriv-
atives that were present in a significantly higher proportion of acute dengue
cases compared to non-dengue cases or healthy control cases (Table S3).
(3) We performed L1-regularized logistic regression (Friedman et al., 2010)
using dengue status as the dependent variable to discover individual
CDR3s and their one-mismatch derivatives that were disproportionately
associated with dengue status (for L1-regularized odds ratios see
Table S3). The area under the receiver operating curve (AUC) is a commonly
used metric for evaluating the performance of binary classifiers; in this study,
it can be interpreted as the probability that the classifier predicts a higher
acute dengue risk for a randomly selected acute dengue case than for a
randomly chosen non-dengue case. The L1-regularized logistic regression
classifier, which used the CDR3s as features, had a leave-pair-out cross-
validation (LPOCV) AUC estimate of 0.777. (4) Lastly, we clustered CDR3s
based on similarities in length and sequence such that each cluster con-
tained CDR3s of the same length with pairwise Hamming distances of %2
(Glanville et al., 2011). Performance of the resulting 470 clusters was
assessed using L1-regularized logistic regression (for predictive clustersInc.
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Convergent Antibody Signatures in Human Dengueand regularized log odds ratios see Table S3). This optimized approach
yielded an AUC of 0.834. Table S3 also lists these statistical measures for
the five CDR3 candidates that were identified using mismatch-based
cross-validation.
CDR3 Clustering
Principal component analysis (PCA) was performed using molecular weight,
isoelectric pH, and hydrophilicity scores for each amino acid for 892 10-mer
and 9,158 13-mer CDR3s. Percent of total variance in the data explained by
the first three principal components is presented in Figures 5A and 5B.
k-means clustering was used to partition the CDR3s using components that
accounted for at least 50% variance, and cluster sizes were optimized with
the cubic clustering criterion fit statistic (data not shown), yielding 400 and
3,000 clusters for the 10-mer and 13-mer CDR3s, respectively.
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